Transfusion ReactionNCT02423135
Detection of Autologous DEHP (DiEthylHexyl Phthalate)-Free Blood Transfusion in Anti-doping
A study testing Autologous blood transfusion in people with Transfusion Reaction, run by Centre Hospitalier Universitaire Vaudois at 1 site in Switzerland.
Trial summary
The aim of the proposed project is to perform a clinical study in which volunteers will receive autologous blood transfusions in DEHP-free blood bags. Read more about this study
- Who is it for?
- Ages 20 to 35 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Transfusion Reaction
- What is being tested?
- Autologous blood transfusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteSwitzerland
- Study dates
- Oct 2014to Feb 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 35 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Have to fill the swiss blood donation formulary
Who cannot join
- Anemia
- Cardiovascular disease
- Neurologic disease
- Not performed a blood donation for 5 weeks ago the start of the study.
- Immunological disease
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
Swiss Laboratory for Doping Analyses
Épalinges, Canton of Vaud, 1066
About this study
Official title: Detection of Autologous DEHP (DiEthylHexyl Phthalate)-Free Blood Transfusion Using a Combination of Multiple Biomarkers in Different Matrices.
The aim of the proposed project is to perform a clinical study in which volunteers will receive autologous blood transfusions in DEHP-free blood bags.
- Conditions
- Transfusion Reaction
- Being tested
- Autologous blood transfusion
- Medical subject headings
- Transfusion Reaction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Autologous blood transfusionBiological
Volunteers make a blood donation and after 36 days of storage this blood is re-infused in the same volunteers.
| Study group | Role | What they receive |
|---|---|---|
| Blood bags without DEHP | Experimental | Intervention : Autologous blood transfusion Receives: Biological: Autologous blood transfusion |
| Blood bags with DEHP | Experimental | Intervention : Autologous blood transfusion Receives: Biological: Autologous blood transfusion |
What is being measured
The primary outcome is the main question the study is designed to answer.
Measurement of blood parameters profile, iron metabolism and genomic compounds
Blood profiling such as measurement of concentration of different blood cells and hemoglobin will be measured up to 15 days after blood-reinfusion. Concentration of free-iron, ferritin and hepcidin will be measured in plasma and serum up to 15 days after blood re-infusion.
Concentration of circulating microRNAs will be measured in plasma also up to 15 days after blood re-infusion. All measures are compared.
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Apr 2015 (estimated)
- Study startOct 2014
- Primary completionJan 2015
- Study completionFeb 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Transfusion ReactionStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire VaudoisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire Vaudois
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nicolas Leuenberger, Centre Hospitalier Universitaire Vaudois
- Investigators
- Nicolas Leuenberger, PhD, Principal investigator, Swiss Laboratory for Doping Analyses
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02423135
- Sponsor's protocol ID
- Protocol 06/14
- Other IDs
- 12C14NL
- Status last verified
- Apr 2015
- First submitted
- 13 Oct 2014
- Last updated
- 22 Apr 2015
- Results posted
- No
- Data monitoring committee
- No
Publications
Leuenberger N, Barras L, Nicoli R, Robinson N, Baume N, Lion N, Barelli S, Tissot JD, Saugy M. Hepcidin as a new biomarker for detecting autologous blood transfusion. Am J Hematol. 2016 May;91(5):467-72. doi: 10.1002/ajh.24313. Epub 2016 Apr 6.
PubMed 26822428
Study at a glance
From the registry record, last updated by the sponsor on 22 Apr 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Detection of Autologous DEHP (DiEthylHexyl Phthalate)-Free Blood Transfusion Using a Combination of Multiple Biomarkers in Different Matrices.
- ClinicalTrials.gov ID
- NCT02423135
- Acronym / sponsor ID
- Protocol 06/14
- Conditions
- Transfusion Reaction
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Centre Hospitalier Universitaire VaudoisUniversity, hospital or other
- Study start
- Oct 2014
- Primary completion
- Jan 2015 (actual)
- Study completion
- Feb 2015 (actual)
- First posted
- 22 Apr 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the proposed project is to perform a clinical study in which volunteers will receive autologous blood transfusions in DEHP-free blood bags.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Blood bags without DEHP | Experimental | Biological: Autologous blood transfusionIntervention : Autologous blood transfusion |
| Blood bags with DEHP | Experimental | Biological: Autologous blood transfusionIntervention : Autologous blood transfusion |
Who may qualify
- Ages
- 20 to 35 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Have to fill the swiss blood donation formulary
Key exclusion criteria (5 listed)
- Anemia
- Cardiovascular disease
- Neurologic disease
- Not performed a blood donation for 5 weeks ago the start of the study.
- Immunological disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Autologous blood transfusionVolunteers make a blood donation and after 36 days of storage this blood is re-infused in the same volunteers. | Biological | Blood bags with DEHP, Blood bags without DEHP |
Primary outcome
Measurement of blood parameters profile, iron metabolism and genomic compounds
Time frame: 1 month
Blood profiling such as measurement of concentration of different blood cells and hemoglobin will be measured up to 15 days after blood-reinfusion. Concentration of free-iron, ferritin and hepcidin will be measured in plasma and serum up to 15 days after blood re-infusion. Concentration of circulating microRNAs will be measured in plasma also up to 15 days after blood re-infusion. All measures are compared.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Apr 2015.
- Derived from this study: PubMed 26822428Leuenberger N, Barras L, Nicoli R, Robinson N, Baume N, Lion N, Barelli S, Tissot JD, Saugy M. Hepcidin as a new biomarker for detecting autologous blood transfusion. Am J Hematol. 2016 May;91(5):467-72. doi: 10.1002/ajh.24313. Epub 2016 Apr 6.
Related trials for Transfusion Reaction
Active, not recruitingObservational study
Mechanisms of Anaphylaxis
Anaphylaxis, Allergy
Not yet recruitingPhase 2
Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs
Transfusion Reaction, Hemolytic
RecruitingPhase 4
Antihistamine for Prevention of HTR After Blood Primed CPB
Blood Transfusion Associated Adverse Reactions
Not yet recruitingObservational study
Incidence of Bleeding, Thrombosis and Transfusion Requirements in ICU Patients With COVID-19 Supported With Veno-venous Extracorporeal Membrane Oxygenation
VV ECMO, Bleeding
RecruitingObservational study
Hip Fracture Surgery Timing and Blood Transfusion Risk in Patients on DOACs
Blood Transfusion, Hip Fracture Surgeries
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nicolas Leuenberger, PhD principal investigator
Swiss Laboratory for Doping Analyses
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Autologous blood transfusion in people with Transfusion Reaction, run by Centre Hospitalier Universitaire Vaudois at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Apr 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Measurement of blood parameters profile, iron metabolism and genomic compounds (time frame: 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02423135, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2015; AzTrials last refreshed its copy on 8 Nov 2026.